Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling

NCT02563327 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention as lead sponsor.

NCT NCT02563327
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02563327 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
TBTC Study 31 PK/PD: Population Pharmacokinetic and Pharmacodynamic Study of Efficacy and Safety of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis in the Study 31 Treatment Trial: Intensive PK Sampling
Lead sponsor
Centers for Disease Control and Prevention
Phase
Phase 3
Overall status
Completed
Start date
January 25, 2016
Completion date
August 30, 2021
Enrollment
2,516 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

tuberculosis